Article Text

Download PDFPDF
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

Statistics from


  • Handling editor Josef S Smolen

  • Contributors All authors were involved with the design, writing, analysis and collection of data.

  • Funding DJW research was supported by Immunomedics, Inc. DJW and DMG were employed at Immunomedics, Inc., when this study was conducted and owned stock in the company. DMG was founder and former Chairman and Chief Scientific Officer, and the inventor or co-inventor on several patents covering milatuzumab.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.